October 1, 2021

This HEDIS®[1] Measurement year (MY) 2021 Public Reporting memo outlines all measures, product lines and indicators that have been approved for public reporting for MY 2021, MY 2022 and MY 2023, as well as all measures, product lines and indicators that will not be publicly reported for MY 2021.

If you have questions about the information included in the tables, contact us through My NCQA (https://my.ncqa.org).

HEDIS Measurement Year	HEDIS Measures
2021	The following first-year and first-year status measures, product lines and indicators will be publicly reported for MY 2021: • Cardiac Rehabilitation (CRE). • Osteoporosis Screening in Older Women (OSW). • Kidney Health Evaluation for Patients with Diabetes (KED). • Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)—Medicare. • Appropriate Treatment for Upper Respiratory Infection (URI)—Medicare. • Appropriate Testing for Pharyngitis (CWP)—Medicare. • Emergency Department Utilization (EDU). • Use of High-Risk Medication Use in Older Adults (DAE)—Rate 2 and Total Rate.
2021	The following measures reported using Electronic Clinical Data Systems (ECDS) will not be publicly reported for MY 2021: • Breast Cancer Screening (BCS-E). • Colorectal Cancer Screening (COL-E). • Follow-Up Care for Children Prescribed ADHD Medication (ADD-E). • Depression Screening and Follow-Up for Adolescents and Adults (DSF-E). • Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E). • Depression Remission or Response for Adolescents and Adults (DRR-E). • Unhealthy Alcohol Use Screening and Follow-Up (ASF-E). • Adult Immunization Status (AIS-E). • Prenatal Depression Screening and Follow-Up (PND-E). • Postpartum Depression Screening and Follow-Up (PDS-E).

[1]HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

NCQA announces the recently approved public reporting decisions for the following measures reported using ECDS and the measurement year in which public reporting will take effect.

HEDIS Measurement Year	HEDIS Measures
2022	The following measures reported using ECDS will be publicly reported for MY 2022: • Adult Immunization Status (AIS-E). • Prenatal Depression Screening and Follow-Up (PND-E). • Postpartum Depression Screening and Follow-Up (PDS-E).
2023	The following measures reported using ECDS will be publicly reported for MY 2023: • Depression Screening and Follow-Up for Adolescents and Adults (DSF-E). • Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E). • Depression Remission or Response for Adolescents and Adults (DRR-E). • Unhealthy Alcohol Use Screening and Follow-Up (ASF-E).

NCQA Copyright Notice and Disclaimer